Novel formulations and modes of delivery of levodopa

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 114-120

  Poewe, Werner ^a   Antonini, Angelo ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

COMT inhibitors; Extended release formulation; Intrapulmonary delivery; Levodopa infusions; Levodopa microtablets

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; UNCLASSIFIED DRUG; XP 21279; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DRUG COMBINATION;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; ENTERAL DRUG ADMINISTRATION; ENZYME INHIBITION; GOLD STANDARD; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; DRUG COMBINATION; PARKINSON DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84920927713     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26078     Document Type: Review

References (55)

1. Birkmayer W, Hornykiewicz O. The effect of L-3, 4-Dioxyphenylalanine (=DOPA) on parkinsonian akinesia. Wien Klin Wochenschr 1961;73:787-788.
2. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
3. Shoulson I, Glaubiger GA, Chase TN. On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
4. Muenter MD, Tyce GM. L-dopa thearapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
5. Lees AJ, Shaw KM, Stern GM. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease. The Lancet 1977;2:1034.
6. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55:S72-S77.
7. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
8. Leenders KL, Poewe WH, Palmer AJ, et al. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986;20:258-262.
9. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
10. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2001;12:1-166.
11. Pletscher A, DaPrada M. Pharmacotherapy of Parkinson's disease: research from 1960 to 1991. Acta Neurol Scand Suppl 1993;146:26-31.
12. Calne DB, Reid JL, Vakil SD, et al. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J 1971;3:729-732.
13. Nutt JG, Woodward WR, Anderson, JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:537-543.
14. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
15. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744.
16. Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord 2012;27:750-753.
17. Kuoppamaki M, Trenkwalder C, Vahteristo M, et al. Phase II proof of concept study to compare a novel levodopa product ODM-101 to levodopa/carbidopa/entacapone in Parkinson's disease patients with response fluctuations (S23.005). Proceedings AAN 2013. Neurology 2013;80(Meeting Abstracts 1):S23.005.
18. Caraco Y, Giladi N, Oren S, et al. Continuous subcutaneous carbidopa improves levodopa pharmacokinetics in Parkinson's disease patients. Mov Disord 2012;27:abstract no. 349.
19. Nissinen E, Mannisto PT. Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. Int Rev Neurobiol 2010;95:73-118.
20. Lees AJ. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci Ther 2008;14:83-93.
21. Lees A, Ferreira J, Costa R, et al. Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's disease patients: BIPARK-II study. J Neurol Sci 2013;333(Abstracts WCN 2013):e116.
22. Poewe WH, Lees AJ, Stern GM. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations. Eur Neurol 1987;27(Suppl 1):93-97.
23. Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989;52:207-212.
24. Mao Z, Hsu A, Gupta S, et al. Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. J Clin Pharmacol 2013;53:523-531.
25. Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011;26:2246-2252.
26. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-356.
27. Stocchi G, Dillmann U, Mahler A, et al. Comparison of IPX066, a novel investigational carbidopa/levodopa(CD-LD) extended-release formulation, and CD-LD-entacapone (CLE) in advanced Parkinson's disease (ASCEND-PD trial). Mov Disord 2012;27:no.437.
28. Lewitt, PA, Ellenbogen, A, Chen, D, et al. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharmacol 2012;35:103-110.
29. Lewitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014;29:75-82.
30. LeWitt P, Friedman H, Giladi N, et al. Accordion pill carbidopa-levodopa for improved symptomatic treatment of advanced Parkinson's disease. Mov Disord 2012;27:S1-S523.
31. Verhagen Metman LSN, Chen C, Cowles V, et al. A randomized, crossover study of DM-1992, a gastroretentive formulation of carbidopa/levodopa in PD patients with motor fluctuations. Mov Disord 2013;28(Suppl 1):31-32.
32. Nyholm D, Lewander T, Gomes-Trolin C, et al. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol 2012;35:111-117.
33. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984;107:487-506.
34. Quinn N, Marsden CD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;2:412-415.
35. Kurlan R, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 1988;23:589-595.
36. Sage JI, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89.
37. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-1703.
38. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
39. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
40. Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013;19:339-345.
41. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-1149.
42. Antonini A, Odin P, Opiano L, et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 2013;120:1553-1558.
43. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-1474.
44. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-149.
45. Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord 2014;20:27-31.
46. Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008;23:1850-1859.
47. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 1991;114:601-617.
48. Stibe CM, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-406.
49. Garcia Ruiz PJ, Sesar IA, Ares PB, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136.
50. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.
51. Caraco Y, Oren S, LeWitt P. Constant therapeutic levodpa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD). Mov Disord 2013;28:S162.
52. Caraco Y, Oren S, Yacoby-Zeevi O, et al. ND0612, a novel formulation of levodopa/carbidopa for continuous, subcutaneous administration, achieves steady-state levodopa plasma concentration in Parkinson's disease patients. Mov Disord 2013;79:56.
53. Freed M, Batycky R, Merica E. Safety, tolerability and levodopa pharmacokinetics following inhaled administration of CVT-301, a levodopa dry poweder aerosol, in healthy, adult subjects. Mov Disord 2013;28:S154.
54. Antonini A, Chaudhuri KR, Martinez-Martin P, et al. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010;24:119-129.
55. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.